Skip to content

Human umbilical cord mesenchymal stem cell transplantation in refractory lupus nephritis: a clinical study

Human umbilical cord mesenchymal stem cell transplantation in refractory lupus nephritis: a clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-17011139
Enrollment
Unknown
Registered
2017-04-13
Start date
2017-04-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Nephritis

Interventions

Treat group:umbilical cord mesenchymal stem cell transplantation

Sponsors

Department of Nephrology; The First Affiliated Hospital of the Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-60 years old male and female; (2) Meet the Emendatory SLE diagnostic criteria of The American rheumatism association (1982); (3) Patient with pathologically confirmed Lupus nephritis III-IV-SIV-GV or III+VIV+ V type; (4) The Clinical diagnosis of refractory with lupus nephritis is confirmed (Proteinuria > 1 g/d After 24 weeks of treatment or down less than 25%, compared with before treatment and exclusion of reversible factors; The SLEDAI score > 8).

Exclusion criteria

Exclusion criteria: (1) With other autoimmune diseases, connective tissue diseases, amyloidosis; (2) The pulmonary artery pressure 50 mmHg or higher; (3) Any more complicated medical problems may interfere with the action or result in increased risk, such as malignant tumor, diabetes, blood disease, heart disease, liver disease, AIDS, viral hepatitis and other acquired and congenital immunodeficiency disease, or has a history of organ transplantation, etc; (4) Allergic to any culture cell component; (5) Clinically active infection; (6) Couldn't understand the potential risks and benefits of research, unable to follow-up assessment as required; (7) No capacity for civil conduct; (8) The history of drug or alcohol abuse; (9) Pregnancy or lactation; (10) Researchers think not appropriate for clinical subjects.

Design outcomes

Primary

MeasureTime frame
24-hours proteinuria;Serum albumin;

Secondary

MeasureTime frame
recurrence rate;remission rate;mortality;complement C3;dsDNA;Sm antibody;Serum creatine;eGFR-EPI;SLEDAI ??;

Countries

China

Contacts

Public ContactZhao Hongwen

Department of Nephrology; the First Affiliated Hospital of the Third Military Medical University

358984844@qq.com+86 13983360655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026